SIGA Technologies, Inc. - 10-K Summary (Fiscal Year Ended Dec 31, 2005)
Business Context and Reporting Period
Company: SIGA Technologies, Inc.
Reporting Period: Fiscal year ended December 31, 2005.
Industry: Biotechnology (Bio-defense, Anti-infectives, Vaccines).
Overview: SIGA is a clinical-stage biotechnology company focused on discovering and developing novel anti-infectives, antibiotics, and vaccines for serious infectious diseases and biological warfare agents. The company has no commercial products and relies on government grants, contracts, and equity financing to fund operations.
Key Financial Metrics
| Metric (in thousands) | 2005 | 2004 |
|---|---|---|
| Revenues | $8,477 | $1,839 |
| Operating Expenses | $11,009 | $11,287 |
| Operating Loss | $(2,532) | $(9,448) |
| Net Loss | $(2,288) | $(9,373) |
| Cash and Cash Equivalents (Year End) | $1,772 | $2,021 |
| Net Cash Used in Operating Activities | $(1,392) | $(4,890) |
| Long-term Obligations | $642 | $4,559 |
| Stockholders' Equity | $3,231 | $4,559 |
Note: 2004 figures include significant non-cash charges for impairment of intangible assets ($2.1M) and in-process R&D ($0.6M).
Material Changes vs. Prior Period
- Revenue Surge: Revenues increased 361% to $8.5 million, driven primarily by the recognition of $6.6 million from NIH SBIR grants awarded in late 2004 for Smallpox and Arenavirus programs, plus new contracts with Saint Louis University and the U.S. Army.
- Reduced Operating Loss: The operating loss narrowed significantly from $9.4 million in 2004 to $2.5 million in 2005. This improvement was due to higher revenues and a 39% reduction in Selling, General, and Administrative (SG&A) expenses (down $1.6M), largely due to lower legal and consulting fees.
- Increased R&D Spend: Research and Development expenses nearly doubled to $8.3 million (up 99%), reflecting preclinical development work for lead programs and staff expansion (scientists increased from 23 to 33).
- Equity Financing: In November 2005, the company raised $1.8 million in net proceeds from a private placement of common stock and warrants.
Guidance, Outlook, Risks, and Unusual Items
- Merger Activity: On March 9, 2006, SIGA entered into a term sheet to merge with PharmAthene, Inc. SIGA shareholders are expected to own approximately 32% of the combined entity. A $3 million bridge note from PharmAthene was initiated to support operations.
- Liquidity: Management believes cash on hand ($1.8M) plus anticipated government funding and the bridge note will support operations beyond March 31, 2007. However, the company expects to continue incurring losses and requires additional capital to achieve profitability.
- Product Pipeline: Lead product SIGA-246 (Smallpox antiviral) received FDA "Fast-Track" status and IND acceptance in December 2005. Phase I trials were planned for 2006. Estimated cost to complete the program is $15M-$20M over 24-36 months.
- Risks:
- Going Concern: The company has an accumulated deficit of $46.5 million and no commercial products. Continued operations depend on securing grants, contracts, or equity financing.
- Revenue Concentration: 87% of 2005 revenue was derived from NIH SBIR grants, which are subject to expiration and renewal uncertainty.
- Legal Proceedings: A lawsuit was filed in February 2006 by Four Star Group alleging breach of contract regarding compensation.
- Unusual Items: A gain of $236,000 was recorded in 2005 due to the decline in fair value of common stock rights and warrants issued in the November financing.
Investor Verification Checklist
- Merger Status: Verify the execution of the definitive merger agreement with PharmAthene and the closing conditions.
- Grant Renewals: Confirm the status of NIH SBIR grants (expiring Sept 2006) and U.S. Army contracts, as these represent the vast majority of revenue.
- Cash Runway: Assess the sufficiency of the $3M bridge note and existing cash to fund operations through the planned Phase I trials for SIGA-246.
- Legal Exposure: Monitor the outcome of the Four Star Group litigation filed in early 2006.
- Stock Dilution: Review the impact of outstanding warrants (approx. 9.4M) and options (approx. 9.4M) on future share count and ownership percentage post-merger.